Nature Reviews Rheumatology最新文献_第5页

Two sides of management recommendations for psoriatic arthritis 银屑病关节炎管理建议的两面性

IF 29.4 1区医学

Nature Reviews Rheumatology Pub Date : 2024-05-21 DOI: 10.1038/s41584-024-01127-3

Ennio Lubrano, Fabio Massimo Perrotta

引用次数: 0

Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development OA 治疗开发中的临床表型、分子内型和治疗类型

IF 29.4 1区医学

Nature Reviews Rheumatology Pub Date : 2024-05-17 DOI: 10.1038/s41584-024-01126-4

Ali Mobasheri, Richard Loeser

引用次数: 0

Can transcriptomics guide the management of SLE-associated APS? 转录组学能否指导系统性红斑狼疮相关 APS 的治疗？

IF 29.4 1区医学

Nature Reviews Rheumatology Pub Date : 2024-05-16 DOI: 10.1038/s41584-024-01123-7

Jason S. Knight, Maria G. Tektonidou

引用次数: 0

Recent advancements in cartilage tissue engineering innovation and translation 软骨组织工程创新和转化的最新进展

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-05-13 DOI: 10.1038/s41584-024-01118-4

Rachel C. Nordberg, Benjamin J. Bielajew, Takumi Takahashi, Shuyan Dai, Jerry C. Hu, Kyriacos A. Athanasiou

{"title":"Recent advancements in cartilage tissue engineering innovation and translation","authors":"Rachel C. Nordberg, Benjamin J. Bielajew, Takumi Takahashi, Shuyan Dai, Jerry C. Hu, Kyriacos A. Athanasiou","doi":"10.1038/s41584-024-01118-4","DOIUrl":"10.1038/s41584-024-01118-4","url":null,"abstract":"Articular cartilage was expected to be one of the first successfully engineered tissues, but today, cartilage repair products are few and they exhibit considerable limitations. For example, of the cell-based products that are available globally, only one is marketed for non-knee indications, none are indicated for severe osteoarthritis or rheumatoid arthritis, and only one is approved for marketing in the USA. However, advances in cartilage tissue engineering might now finally lead to the development of new cartilage repair products. To understand the potential in this field, it helps to consider the current landscape of tissue-engineered products for articular cartilage repair and particularly cell-based therapies. Advances relating to cell sources, bioactive stimuli and scaffold or scaffold-free approaches should now contribute to progress in therapeutic development. Engineering for an inflammatory environment is required because of the need for implants to withstand immune challenge within joints affected by osteoarthritis or rheumatoid arthritis. Bringing additional cartilage repair products to the market will require an understanding of the translational vector for their commercialization. Advances thus far can facilitate the future translation of engineered cartilage products to benefit the millions of patients who suffer from cartilage injuries and arthritides. In this Review, the current landscape of tissue engineering for repair of articular cartilage is discussed, with reference to advances in cell sources, bioactive stimuli and the use of scaffolds, and with consideration of the challenges that result from the inflammatory articular environments in osteoarthritis and rheumatoid arthritis.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140915118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bone-modifying drugs slow OA progression 骨修饰药物可减缓 OA 的进展。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-05-07 DOI: 10.1038/s41584-024-01122-8

Sarah Onuora

引用次数: 0

Rethinking antiphospholipid syndrome to guide future management and research 重新思考抗磷脂综合征，为未来的管理和研究提供指导

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-05-03 DOI: 10.1038/s41584-024-01110-y

Jason S. Knight, Doruk Erkan

引用次数: 0

Adropin inhibits fibrosis in SSc 阿托品能抑制 SSc 的纤维化

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-05-03 DOI: 10.1038/s41584-024-01121-9

Robert Phillips

引用次数: 0

Relapsing polychondritis: clinical updates and new differential diagnoses 复发性多软骨炎：临床更新和新的鉴别诊断

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-05-02 DOI: 10.1038/s41584-024-01113-9

Philippe Mertz, Nathalie Costedoat-Chalumeau, Marcela A. Ferrada, Guillaume Moulis, Arsène Mekinian, Peter C. Grayson, Laurent Arnaud

{"title":"Relapsing polychondritis: clinical updates and new differential diagnoses","authors":"Philippe Mertz, Nathalie Costedoat-Chalumeau, Marcela A. Ferrada, Guillaume Moulis, Arsène Mekinian, Peter C. Grayson, Laurent Arnaud","doi":"10.1038/s41584-024-01113-9","DOIUrl":"10.1038/s41584-024-01113-9","url":null,"abstract":"Relapsing polychondritis is a rare inflammatory disease characterized by recurrent inflammation of cartilaginous structures, mainly of the ears, nose and respiratory tract, with a broad spectrum of accompanying systemic features. Despite its rarity, prompt recognition and accurate diagnosis of relapsing polychondritis is crucial for appropriate management and optimal outcomes. Our understanding of relapsing polychondritis has changed markedly in the past couple of years with the identification of three distinct patient clusters that have different clinical manifestations and prognostic outcomes. With the progress of pangenomic sequencing and the discovery of new somatic and monogenic autoinflammatory diseases, new differential diagnoses have emerged, notably the vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome, autoinflammatory diseases and immune checkpoint inhibitor-related adverse events. In this Review, we present a detailed update of the newly identified clusters and highlight red flags that should raise suspicion of these alternative diagnoses. The identification of these different clusters and mimickers has a direct impact on the management, follow-up and prognosis of patients with relapsing polychondritis and autoinflammatory syndromes. Relapsing polychondritis, a rare inflammatory disorder that affects cartilaginous structures, presents challenges in diagnosis owing to overlapping symptoms with other conditions. This Review provides a clinical update on relapsing polychondritis, emphasizing the importance of distinguishing this disease from similar conditions.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140819419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Granzyme serine proteases in inflammation and rheumatic diseases 炎症和风湿病中的颗粒酶丝氨酸蛋白酶

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-04-30 DOI: 10.1038/s41584-024-01109-5

Alexandre Aubert, Karen Jung, Sho Hiroyasu, Julian Pardo, David J. Granville

{"title":"Granzyme serine proteases in inflammation and rheumatic diseases","authors":"Alexandre Aubert, Karen Jung, Sho Hiroyasu, Julian Pardo, David J. Granville","doi":"10.1038/s41584-024-01109-5","DOIUrl":"10.1038/s41584-024-01109-5","url":null,"abstract":"Granzymes (granule-secreted enzymes) are a family of serine proteases that have been viewed as redundant cytotoxic enzymes since their discovery more than 30 years ago. Predominantly produced by cytotoxic lymphocytes and natural killer cells, granzymes are delivered into the cytoplasm of target cells through immunological synapses in cooperation with the pore-forming protein perforin. After internalization, granzymes can initiate cell death through the cleavage of intracellular substrates. However, evidence now also demonstrates the existence of non-cytotoxic, pro-inflammatory, intracellular and extracellular functions that are granzyme specific. Under pathological conditions, granzymes can be produced and secreted extracellularly by immune cells as well as by non-immune cells. Depending on the granzyme, accumulation in the extracellular milieu might contribute to inflammation, tissue injury, impaired wound healing, barrier dysfunction, osteoclastogenesis and/or autoantigen generation. Granzyme serine proteases are known for their perforin-dependent cytotoxic activities, but evidence also indicates that they have a range of non-cytotoxic, pro-inflammatory intracellular and extracellular functions. In this Review, the authors discuss granzyme biology with an emphasis on its involvement in rheumatic disease pathology.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140817695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treat-to-target or treat-to-dissolve strategy to improve gout treatment 采取 "靶向治疗 "或 "溶解治疗 "策略改进痛风治疗

IF 29.4 1区医学

Nature Reviews Rheumatology Pub Date : 2024-04-26 DOI: 10.1038/s41584-024-01117-5

Pascal Richette, Nicola Dalbeth

引用次数: 0